ReviewStem cell research & therapy2026
Activation of Nrf2 with natural flavonoids and mesenchymal stromal/stem cells: mechanisms and therapeutic potential for inflammatory diseases.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Redox balance is crucial for maintaining normal physiological functions. Its disruption by oxidative stress can trigger or exacerbate a series of pathological cascades, ultimately contributing to various chronic diseases, particularly inflammatory disorders. Inhibiting oxidative stress and its associated pathological cascades may alleviate these diseases, a process often linked to the activation of nuclear factor erythroid 2-related factor 2 (Nrf2). Initially characterized as a redox-sensitive transcription factor, Nrf2 is now recognized as a pivotal regulator of an extensive network of antioxidant genes, effectively counteracting oxidative stress and its detrimental effects. Consequently, advances in understanding Nrf2 activators and their regulatory mechanisms have accelerated the development of Nrf2-targeted therapies, demonstrating significant potential for preventing and treating chronic inflammation diseases. Many natural phytochemicals, particularly flavonoids, have been identified as Nrf2 activators that can ameliorate inflammatory responses. Furthermore, therapy with mesenchymal stromal/stem cells (MSCs) is a highly researched treatment approach with the potential to confer immunomodulatory, anti-inflammatory, anti-apoptotic and antimicrobial effects. Owing to their superior safety profile compared to conventional therapeutics, MSCs are gaining prominence as sustainable long-term treatment options, although their precise molecular mechanisms remain to be fully elucidated. This review focuses on the activation mechanisms of Nrf2 and its clinical and preclinical inducers, with particular emphasis on the mechanistic insights and therapeutic applications of natural flavonoids and MSCs in the prevention or treatment of inflammatory diseases. More importantly, it summarizes the profound role of flavonoid-MSCs combinatorial therapy in the intervention of inflammatory diseases, pointing out novel therapeutic strategies and future prospects for modulating the Nrf2 signaling pathway in the treatment of inflammatory disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.